Project Grant R01HL180443
Award Date 8/10/25
Completion Date 5/31/29
Dollars Obligated $595K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This $721,826 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify molecular mechanisms regulating alveolar matrix fibroblast function and their role in supporting vascular capillary formation. The research is being conducted by Children's Hospital Medical Center in Cincinnati, Ohio to advance the understanding of alveolar septation and septal wall maturation, which is...
- The National Heart Lung and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $172,724 project grant to The Regents of the University of California, San Francisco (UCSF) on February 28, 2025. The grant supports research to investigate the epigenetic signatures and gene regulatory networks driving the trans-differentiation of alveolar type II (AT2) cells into airway-like basal cells under homeostatic conditions and in the context of fibrotic...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $629,498 to The Trustees of the University of Pennsylvania (UEI GM1XX56LEP58) to conduct research aimed at deciphering the molecular mechanisms underlying pediatric interstitial lung disease (CHILD). The key objectives are to: Interrogate the anomalous development of the lung epithelium in CHILD by defining the impact of a specific SFTPC gene mutation on alveolar...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $750,162 to The Children's Hospital of Philadelphia (CHOP) to conduct research aimed at understanding the role of lymphatic dysfunction in the development of post-lung transplant bronchiolitis obliterans syndrome (BOS), a serious complication. The research project will use murine models to investigate the mechanisms of lymphatic vascular function after...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $188,892 Project Grant to the University of Washington to support research on the role of CD163+ blood monocytes and lung macrophages in progressive pulmonary fibrosis. This 5-year grant, starting August 1, 2025, will fund a physician-scientist's research plan that leverages the university's expertise in immunology, bioinformatics, and lung biology to...
- This Project Grant award for $879,567.00, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on lung injury in pediatric hematopoietic cell transplant (HCT) recipients. The research team at The Children's Hospital of Philadelphia (CHOP) will conduct a comprehensive characterization of the clinical, proteomic, and cell-free DNA biomarker profiles associated with the development of lung injury after HCT in...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $657,308 to The Children's Hospital of Philadelphia (CHOP) to conduct research on the CXCL12 signaling axis and its role in pulmonary arterial heterogeneity, development, and disease. The key objectives of this 12-month project are to: 1) define the spatiotemporal role of CXCL12 signaling in pulmonary vascular development, 2)...
- This $136,050 Project Grant was awarded on June 30, 2025 by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, to Tufts University School of Medicine. The grant supports research to characterize lung resident B1 cells and their impact on lung homeostasis during development. The research aims to investigate the functional role of B1 cells in developing lungs and their contribution to maintaining lung homeostasis, which...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $166,395 to Columbia University to conduct a 5-year research project on the impact of hyperoxia (excess oxygen) on the function of respiratory progenitor cells in neonates. The project aims to develop a better understanding of the mechanisms by which post-natal lung development occurs in the face of injurious agents like oxygen...